金令牌首页 金令牌猎头 十佳职业经理人评选 最佳雇主评选 加入俱乐部 《职业经理人周刊》 会员区 薪酬调查报告 | 登录 |
职业经理人俱乐部首页
>> 医药医疗 >> Hudson >> 企业信息
企业编号:C001464H09A02 [查询]
Hudson |
金令牌首页 金令牌猎头 十佳职业经理人评选 最佳雇主评选 加入俱乐部 《职业经理人周刊》 会员区 薪酬调查报告 | 登录 |
Hudson |
·国际业务部总经理 | 年薪:面议 |
Hudson (NASDAQ:HHGP) is one of the world’s leading professional recruitment, search, recruitment and talent management solutions providers. We have many of the Global 1000 companies as our clients and serve many clients on a multi-national basis. Hudson has nearly 3,000 staff worldwide serving clients and candidates in more than 20 countries. In the Asia Pacific region, Hudson is one of the largest professional recruitment firms and has been accredited with the ISO 9001 certification. Our multi-lingual consultants have the local knowledge and the connections to attract candidates from a vast pool of local professionals. We have offices in Beijing, Guangzhou, Hong Kong, Shanghai and Singapore, supported by the global resources of Hudson. Hudson in Asia accomplishes this goal through the integrated efforts of three core areas: PROFESSIONAL RECRUITMENT - specialised services to attract and select talent from middle to senior level positions. MANAGED SOLUTIONS - improve the quality of hire, retention rates, time to fill, administrative processes and management reporting. TALENT MANAGEMENT - provides the framework for attracting, selecting, engaging and developing employees. Our high profile newspaper and internet advertising, along with the strong Hudson brand, ensures the consistent attraction of high calibre candidates. In addition, Hudson has built up an extensive database of candidates in Asia and has sophisticated search and selection tools which enable us to find the right candidates for our clients. [收起简介] |
1、上海医药收购集团资产 7月29日,公司公告,拟收购河南商丘新先锋药业有限公司40%股权。 河南商丘新先锋药业有限公司是上海新先锋药业与原商丘市健民药业公司2006年共同出资组建的医药分销企业。上海新先锋药业持有40%股权,其他5位自然人股东合并持有该公司60%股权。而上海新先锋药业是上药集团的控股子公司。 公开资料显示,河南商丘新先锋药业注册资本4000万元,2009年1至6月公司实现销售收入2.88亿元,净利润43.86万元;截至2009年6月底,该公司账面净资产为4274.92万元。 “从业绩上看,这家公司并不优秀,上海医药应该是看中其在河南当地的网络布局,这对分销企业至关重要。”一位医药分析师指出。 上海医药董秘曹伟荣7月29日接受记者采访时表示,这是上海医药第一次进入河南分销市场,收购集团资产是大股东重组方案的内容之一,上海医药目前大部分的分销收入来自上海和华东市场,未来希望进一步向全国市场拓展分销网络。 上海医药是上海市场医药分销龙头企业之一,分销业务占上海市场份额50%,占华东地区20%。但其业务范围多局限于上海周边,并且以医院销售为主。多年来,“走出上海”,在上海以外的区域加快拓展是公司的重要战略之一。 对于接下来是否还会有陆续的资产注入,曹伟荣称,这要看大股东的安排,目前还不好说。6月中旬以 …… [详细信息] |